The Prevalence and Biochemical Profiles of EDTA-Dependent Pseudothrombocytopenia in a Generally Healthy Population
Yufei Xiao,Shuihong Yu,Yang Xu
DOI: https://doi.org/10.1159/000373915
2015-01-01
Acta Haematologica
Abstract:Ethylenediaminetetraacetic acid-dependent pseudothrombocytopenia (EDTA-PTCP) is a phenomenon of spuriously low platelet counts measured by automated complete blood count (CBC) analyzers. The onset of EDTA-PTCP is triggered by EDTA-dependent autoantibodies that recognize the platelet membrane glycoprotein IIb-IIIa, resulting in platelet activation and aggregation [1,2]. The reported prevalence of EDTA-PTCP is variable, ranging from 0.07 to 0.2% of all blood counts [3,4]. EDTA-PTCP is more common in hospitalized patients, especially in those with thrombocytopenia referred to the hematology clinic [5]. The prevalence and risk factors of EDTA-PTCP in healthy populations are not fully understood. In this study, we sought to determine the prevalence and biochemical profiles of EDTA-PTCP in a generally healthy population. We retrospectively reviewed the laboratory data of 190,940 individuals who received yearly checkups between April 2010 and September 2012 in the Second Affiliated Hospital, Zhejiang University School of Medicine. The diagnostic criteria of EDTA-PTCP were adapted from Lippi and Plebani [1] with minor modifications: (1) platelet count is less than 80 × 109/l in EDTA-anticoagulated blood measured by automatic CBC analyzers, (2) lack of signs or symptoms of bleeding, and (3) platelet clumps were observed on a Wright-Giemsa-stained blood smear. The study was performed in accordance with the Declaration of Helsinki, and was approved by the Institutional Review Board of The Second Affiliated Hospital, Zhejiang University School of Medicine. For the case-control study, the non-PTCP controls were randomly selected based on a computer-generated randomization protocol.Peripheral blood samples were taken in the morning following an overnight fast. CBC was performed by using EDTA-anticoagulated blood on the automatic blood analyzer (Beckman-Coulter LH750, USA) within 3 h at room temperature. Biochemical parameters were measured using serum blood after centrifugation on the automatic biochemistry analyzer (Beckman-Coulter AU5431). For patients with an initial platelet count of 80 × 109/l or less, blood was recollected and CBC was repeated using EDTA- and citrate-anticoagulated samples, respectively. Wright-Giemsa-stained blood smears were inspected under a light microscope to detect the presence of platelet clumps. The data were presented as means and ranges, or means ± SD, and were analyzed using the software SPSS 13.0. A χ2 test was performed to correlate the demographic features of patients to the prevalence of EDTA-PTCP. The Mann-Whitney rank-sum test was used for comparison of biochemical parameters between patient and control groups. p < 0.05 was considered statistically significance.Among 190,940 subjects, 1,288 (0.67%) had initial platelet counts between 80 × 109/l and 100 × 109/l, and 657 (0.34%) had platelet counts less than 80 × 109/l. In 241 subjects with platelet counts of 80-100 × 109/l and concurrent flags of platelet clumping present on the CBC analyzer, no platelet clumps were found in blood smears. Of the 657 subjects with platelet counts less than 80 × 109/l, 462 had clumping flags on the CBC analyzer. After inspecting all the 657 blood smears, 84 were finally diagnosed as EDTA-PTCP.The prevalence of EDTA-PCTP in our cohort was 0.044% (84/190,940). Among the patients with EDTA-PTCP were 56 males (66.7%) and 28 females (33.3%), and the median age was 50 years (range: 24-79). The median platelet count was 43 × 109/l (range: 19-75 × 109/l) in the presence of EDTA and 165 × 109/l (range: 114-247 × 109/l) in citrated blood. The prevalence of EDTA-PTCP increased with age in our cohort (fig. 1a). The population older than 50 years had a significantly higher prevalence than those up to 50 years: 0.078 versus 0.031%, p < 0.001 (fig. 1b). EDTA-PTCP was more common in males than in females (ratio of males to females is 1.6) although the difference did not reach statistical significance (0.051 vs. 0.035%, p > 0.05). Interestingly, when the cohort was divided based on the age of 50 years, a significant male prevalence was found in the population older than 50 years (0.098 vs. 0.042%, p < 0.05), whereas prevalence was comparable between the males and females in the population of 50 years or younger (p > 0.05). Similarly, males over 50 years have a significantly higher PTCP prevalence than the male or female subgroup of 50 years or younger (p < 0.001). Thus, males older than 50 years are at higher risk for EDTA-PTCP (table 1).To determine the effect of biochemical profiles on PTCP prevalence, 84 subjects with EDTA-PTCP were compared with 150 randomly selected non-PTCP controls. As shown in table 2, the age and sex distributions were balanced between EDTA-PTCP and control groups (p > 0.05), neither blood pressure nor BMI affects the prevalence of PTCP (p > 0.05). Among biochemical parameters, the levels of glucose, high-density lipoprotein, low-density lipoprotein, γ-glutamyl transpeptidase, albumin, and total protein were not significantly different between the two groups (table 3). However, the levels of alanine transaminase (ALT), aspartate transaminase (AST), alkaline phosphatase (ALP), lactate dehydrogenase (LDH), and uric acid were significantly higher in the PTCP group (p < 0.05; table 3). Renal functions including nitrogen urea and creatinine were not statistically different between the PTCP and control groups (table 3).Clinically, EDTA-PTCP does not pose any hemorrhagic risk; however, failure to recognize this artifact could lead to unnecessary bone marrow aspiration and inappropriate therapy such as platelet transfusion, corticosteroid, or even splenectomy [6]. To rule out EDTA-PTCP in patients with thrombocytopenia, several approaches have been proposed to prevent platelet clumping, e.g. use of alternative anticoagulants or additives including sodium citrate, heparin, aminoglycosides, calcium chloride, and magnesium sulfate [7,8,9,10].The prevalence of EDTA-PTCP in healthy populations remains poorly understood since most epidemiological studies have been carried out in patient populations [11,12,13]. An Italian study over a 10-year period reported an EDTA-PTCP prevalence of 0.11% [3]. Recently, an Israeli study estimated that the 5-year cumulative prevalence of EDTA-PTCP was 0.27%, 2.5-fold higher than the point prevalence of 0.11% [14]. We focused on the characteristics of EDTA-PTCP in a cohort receiving yearly health examinations. The prevalence of EDTA-PTCP of this generally healthy cohort was 0.044%. We did not inspect the blood smears from patients whose platelet counts were between 80 × 109/l and 100 × 109/l, so the actual EDTA-PTCP prevalence will be slightly higher than 0.044%. It is not surprising that fewer patients with EDTA-PTCP were identified in apparently normal subjects than in patients with a variety of diseases. Berkman et al. [15] found that only 2 of 54 patients with EDTA-PTCP had no concurrent diseases and were asymptomatic. Maslanka et al. [16] suggested that the EDTA-PTCP prevalence was 0.013% in blood donors. Sweeney et al. [17] reported a relatively high prevalence of 0.2% in plateletpheresis donors possibly due to a limited cohort size.The prevalence of EDTA-PTCP was generally believed to not be affected by age or sex [1]. Indeed, Bizzaro [3] found that EDTA-PTCP was uniformly present in every age group. However, we showed that the prevalence of EDTA-PTCP is increased with age, and a significant increase of EDTA-PTCP was observed among the group over 50 years. In addition, there are significantly more males with EDTA-PTCP than females in the cohort older than 50 years, which is consistent with the data from Bizzaro [3].The autoantibodies against platelet membrane glycoprotein can be detected in 50-80% of patients with EDTA-PCTP [3,18,19]. Other autoantibodies such as anticardiolipin and antinuclear antibodies which are likely to cross-react with the platelet membrane antigens are also found in patients with EDTA-PTCP [18]. Although the autoantibodies were not determined, they were possibly present in our cohort of healthy individuals. These autoantibodies may represent naturally occurring antibodies without pathological significance, and play a physiological role in the removal of senescent circulating platelets [3,18].The risk factors for EDTA-PTCP have been extensively investigated. Hospitalization, medications, and underlying diseases are considered to increase the incidence of EDTA-PTCP [1,20]. For instance, EDTA-PTCP has been documented in patients with a wide variety of disorders, including autoimmune disease [15], viral [21] and bacterial infection, chronic liver diseases [15], metabolic syndromes, malignancies [15,22], and even in patients undergoing allogeneic stem cell transplantation [23]. However, no specific disease is strongly correlated with the development of EDTA-PTCP. The biochemical profiles in EDTA-PTCP are not fully evaluated. Isik et al. [20] showed that the levels of cholesterol, low-density lipoprotein, high-density lipoprotein, and triglyceride were not significantly different between the EDTA-PTCP and control groups. In this study, we found that ALT, AST, ALP, LDH, and uric acid were significantly higher in the PTCP group when compared with controls. ALT and AST are common markers of hepatocellular damage, and increases in ALP and LDH are likely related to cholestatic conditions. Serum uric acid is often considered as an independent risk factor for cardiovascular disease and diabetes, both of which are associated with EDTA-PTCP [24,25]. Since these parameters are all within the normal ranges, the biochemical alterations may represent the influence of a higher degree of morbidity in EDTA-PTCP subjects.In conclusion, our findings show a relatively low prevalence of EDTA-PTCP in a generally healthy population, and that EDTA-PTCP is more common in males older than 50 years. Changes in biochemical profile may reflect underlying the pathologic conditions that are linked to EDTA-PTCP.This study was supported by the National Basic Research Program of China (No. 2013CB911303), National Natural Science Foundation of China (No. 30973371), and Natural Science Foundation of Zhejiang Province of China (No. Y207111).